Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00789022

Enrollment

Registered

2008-11-11

Start date

2009-01-31

Completion date

Unknown

Last updated

2008-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brief Psychotic Episode, Schizoaffective Disorder, Schizophrenia, Schizophreniform

Keywords

First-Psychotic-Episode (FPE), Glutamatergic system, Glycine, D-Serine, Oxytocin, Estrogen

Brief summary

The goal of our research is to check the levels of D-Serine, Glycine, and other Glutamatergic amino acids, in patients with First Psychotic Episode (FPE). These patients are in the early stage of the disease, treated with neuroleptics for short periods of time, and are usually hospitalized for the first time. The hypothesis of the research is that we will find low levels of Glycine and D-Serine in these patients. Following an Anti-psychotic treatment we will expect these levels to return to the norm, and that this correction will be accompanied by a reduction of positive and negative symptoms. In addition, we will check the D-Serine and Glycine levels in the plasma of first degree relatives of the patients and a group of healthy subjects. The results of this study might support the hypothesis that the Glutamatergic system in involved in the pathology of Schizophrenia from it's early stages. In addition, we will check the levels of Oxytocin and Estrogen in the plasma of patients in FPE. Our hypothesis is that we will find low levels of Estrogen and High levels of Oxytocin in this group of patients. The results of the study might support the hypothesis that Estrogen and Oxytocin are involved in the pathology of Schizophrenia from it's early stages.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects between 18-60 years * Clinical Diagnosis of Schizophrenia, Schizophreniphorm disorder, Schizoaffective Disorder, Brief esychotic episode

Exclusion criteria

* two years or more of positive symptoms * Neuroleptic treatment for more then twe weeks in the prior month, or for more then six weeks at any time. * Drug induced psychotic episode

Design outcomes

Primary

Measure	Time frame
Glycine and D-Serine levels in the plasma.	6-8 weeks

Countries

Israel

Contacts

Primary ContactUri Nitzan, Md

urini@clalit.org.il00-972-9-7478532

Backup ContactUriel Levi-Herscho, MD

uriel heresco-levy [urielh@ekmd.huji.ac.il]00-972-2-5316906

Outcome results